GlassScriptPhysician profile
Leticia Gonzalez
NPI 1174616577
$6,084.36
in general payments reported to CMS, 2019-2025
36 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $801 · 2021: $1,478 · 2022: $1,331 · 2023: $588 · 2024: $133 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,509.23 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $708.12 | 2019-2023 | Arexvy, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $422.08 | 2019-2022 | |
| Astellas Pharma US INC | $402.23 | 2019-2023 | Myrbetriq |
| Avanir Pharmaceuticals, INC. | $354.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $317.84 | 2019-2023 | |
| Gilead Sciences, INC. | $271.72 | 2019-2020 | |
| Lilly USA, LLC | $232.65 | 2019-2023 | Jardiance, Mounjaro |
| Abbvie INC. | $220.41 | 2021-2023 | |
| Intra-Sana Laboratories | $218.57 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Pfizer INC. | $180.11 | 2019-2023 | |
| Amarin Pharma, INC. | $160.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.73 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $105.93 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.78 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $83.41 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $82.37 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $63.94 | 2022 | |
| Abbott Laboratories | $57.37 | 2022-2023 | Freestyle Libre 2 |
| Mallinckrodt Enterprises LLC | $56.56 | 2019 | |
| Boston Scientific Corporation | $54.21 | 2023 | Wavewriter Alpha Prime 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $48.26 | 2019 | |
| Dexcom, INC. | $45.65 | 2021-2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $37.76 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $35.33 | 2019 | |
| Amgen INC. | $28.53 | 2020 | |
| Genentech USA, INC. | $24.21 | 2021 | |
| Bausch Health US, LLC | $22.50 | 2019 | |
| Exact Sciences Corporation | $21.93 | 2023 | Cologuard Collection Kit |
| Cumberland Pharmaceuticals, INC. | $21.06 | 2023 | Kristalose |
| Smith+Nephew, INC. | $20.17 | 2023 | Collagenase Santyl |
| Neurocrine Biosciences, INC. | $19.90 | 2021 | |
| Hologic Sales and Service, LLC | $19.63 | 2019 | |
| Lundbeck LLC | $15.81 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $15.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leticia Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.